WO2012016427A1 - Milieu de culture de cellules de porc - Google Patents
Milieu de culture de cellules de porc Download PDFInfo
- Publication number
- WO2012016427A1 WO2012016427A1 PCT/CN2011/001253 CN2011001253W WO2012016427A1 WO 2012016427 A1 WO2012016427 A1 WO 2012016427A1 CN 2011001253 W CN2011001253 W CN 2011001253W WO 2012016427 A1 WO2012016427 A1 WO 2012016427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serum
- porcine
- cell culture
- culture medium
- pig
- Prior art date
Links
- 239000001963 growth medium Substances 0.000 title abstract description 10
- 210000002966 serum Anatomy 0.000 claims abstract description 79
- 230000001605 fetal effect Effects 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 68
- 239000006143 cell culture medium Substances 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 53
- 210000002950 fibroblast Anatomy 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000007640 basal medium Substances 0.000 claims description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 11
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 11
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 11
- 238000004113 cell culture Methods 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 102000006771 Gonadotropins Human genes 0.000 claims description 6
- 108010086677 Gonadotropins Proteins 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000002622 gonadotropin Substances 0.000 claims description 6
- 210000003292 kidney cell Anatomy 0.000 claims description 6
- 210000000287 oocyte Anatomy 0.000 claims description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 5
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 229940116977 epidermal growth factor Drugs 0.000 claims description 5
- 210000003754 fetus Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 229940054269 sodium pyruvate Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 claims description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 3
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 235000019743 Choline chloride Nutrition 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960003178 choline chloride Drugs 0.000 claims description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 230000005251 gamma ray Effects 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- YODUIMCJDQUOPA-QRPNPIFTSA-M sodium;(2s)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC1=CC=C(O)C=C1 YODUIMCJDQUOPA-QRPNPIFTSA-M 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- 229930182816 L-glutamine Natural products 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims 1
- PANBYUAFMMOFOV-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [Na].OS(O)(=O)=O PANBYUAFMMOFOV-UHFFFAOYSA-N 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 description 71
- 230000012010 growth Effects 0.000 description 25
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- -1 serum Substances 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- WLGOTMXHWBRTJA-GACYYNSASA-N murodermin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N1)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC=2NC=NC=2)NC(=O)[C@H](CCSC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N2)C(C)C)=O)CSSC1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=C(O)C=C1 WLGOTMXHWBRTJA-GACYYNSASA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
Definitions
- the method for preparing the porcine cell culture medium of the present invention further comprises the following steps:
- a further aspect of the invention relates to the use of fetal pig serum prepared as described above in porcine cell culture and/or in the preparation of porcine cell culture medium.
- the pig cells include, but are not limited to, primary porcine fibroblasts, porcine kidney cells, porcine cardiomyocytes, porcine oocytes, porcine vascular endothelial cells, and the like.
- the artificial medium 1 is dissolved in sterile purified water, and the fetal pig serum is added according to the formula ratio, and the sterile purified water is added to the required volume, and then the additive factor combination 1 is added.
- the pig cell culture medium was thus prepared.
- tissue block attachment method DMEM + 15% FBS + double antibody
- the growth curve of the porcine cells cultured in the above three kinds of porcine cell culture medium for 10-16 days is as shown in Fig. 4, wherein the growth state optical density values of the cells cultured in the porcine cell culture medium A, B, and C by the MTT method are shown in Table 8. Shown.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un milieu de culture de cellules de porc, comprenant un milieu de culture de base et du sérum de porc fœtal. L'invention concerne en outre un procédé de culture des cellules de porc, du sérum de porc fœtal, et une utilisation du sérum de porc fœtal dans la culture des cellules de porc ou dans la préparation du milieu de culture des cellules de porc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010242482.3 | 2010-08-02 | ||
| CN201010242482.3A CN102344904B (zh) | 2010-08-02 | 2010-08-02 | 一种猪细胞培养基 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012016427A1 true WO2012016427A1 (fr) | 2012-02-09 |
Family
ID=45543978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2011/001253 WO2012016427A1 (fr) | 2010-08-02 | 2011-08-01 | Milieu de culture de cellules de porc |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102344904B (fr) |
| WO (1) | WO2012016427A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105087461A (zh) * | 2015-06-18 | 2015-11-25 | 上海源培生物科技股份有限公司 | 一种pk细胞培养基 |
| CN105647848A (zh) * | 2016-02-25 | 2016-06-08 | 苏州红冠庄药物研究有限公司 | 鹿血清的分离制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1212009A (zh) * | 1996-01-09 | 1999-03-24 | 加利福尼亚大学董事会 | 有蹄动物胚胎干样细胞、制法及用该细胞产生转基因的有蹄动物的方法 |
| WO1999024556A1 (fr) * | 1997-11-12 | 1999-05-20 | Vts Holdings Llc | Nouveau milieu de culture comprenant du serum foetal porcin |
| WO2002010337A2 (fr) * | 2000-07-28 | 2002-02-07 | Infigen, Inc. | Methode de clonage de porcs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6043092A (en) * | 1996-03-18 | 2000-03-28 | University Of Pittsburgh | Cell culture media for mammalian cells |
| WO2005105992A1 (fr) * | 2004-04-21 | 2005-11-10 | New York Eye & Ear Infirmary | Formulations de culture de chondrocytes |
| CN101429492B (zh) * | 2008-12-12 | 2010-10-06 | 深圳华大基因科技有限公司 | 一种猪卵母细胞体外培养成熟方法 |
-
2010
- 2010-08-02 CN CN201010242482.3A patent/CN102344904B/zh not_active Expired - Fee Related
-
2011
- 2011-08-01 WO PCT/CN2011/001253 patent/WO2012016427A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1212009A (zh) * | 1996-01-09 | 1999-03-24 | 加利福尼亚大学董事会 | 有蹄动物胚胎干样细胞、制法及用该细胞产生转基因的有蹄动物的方法 |
| WO1999024556A1 (fr) * | 1997-11-12 | 1999-05-20 | Vts Holdings Llc | Nouveau milieu de culture comprenant du serum foetal porcin |
| WO2002010337A2 (fr) * | 2000-07-28 | 2002-02-07 | Infigen, Inc. | Methode de clonage de porcs |
Non-Patent Citations (4)
| Title |
|---|
| DAEN, FERDINAND P. ET AL.: "Serum factor(s) stimulating cumulus expansion in porcine oocyte-cumulus complexes matured and fertilized in vitro.", CELL STRUCTURE AND FUNCTION, vol. 20, no. 3, 31 January 1995 (1995-01-31), pages 223 - 231 * |
| LI, MENGBIN ET AL.: "Influence of Xeno-Serum on Accommodation Model of Porcine Aortic Endothelial Cell", SHANXI MEDICAL JOURNAL, vol. 35, no. 11, 30 November 2006 (2006-11-30), pages 1403 - 1404, 1410 * |
| LIU, PENG ET AL.: "Proliferation of Dermal Fibroblasts from Human, Yorkshire Pigs or SD Rats Cultured in DMEM with Different Concentrations of Serum", JOURNAL OF PRACTICAL STOMATOLOGY, vol. 20, no. 1, 31 January 2004 (2004-01-31), pages 16 - 19 * |
| WEINGARTL, H. M. ET AL.: "Continuous porcine cell lines developed from alveolar macrophages: Partial characterization and virus susceptibility.", JOURNAL OF VIROLOGICAL METHODS, vol. 104, no. 2, 13 June 2002 (2002-06-13), pages 203 - 216, XP002604365 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102344904A (zh) | 2012-02-08 |
| CN102344904B (zh) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ragnarsson et al. | Basic biological sciences isolation and growth of human periodontal ligament cells in vitro | |
| CN101326281A (zh) | 用源自胎盘的干细胞制备少突胶质细胞 | |
| CN102344906B (zh) | 一种毛囊干细胞的分离培养方法 | |
| CN104946587B (zh) | 一种淋巴细胞无血清培养基及其制备方法和应用 | |
| CN107881197A (zh) | 一种永生化奶牛瘤胃上皮细胞系及其构建方法 | |
| CN103881968A (zh) | 一种鹅卵巢卵泡原代颗粒细胞的分离培养方法 | |
| CN108504625B (zh) | 一种小鼠成纤维细胞及其用途 | |
| CN106038597A (zh) | 间充质干细胞在制备治疗急性肺损伤制剂中的应用 | |
| CN102226169B (zh) | 山羊毛囊外根鞘细胞系的构建方法 | |
| WO2012016427A1 (fr) | Milieu de culture de cellules de porc | |
| CN102586176A (zh) | 一种新型的无动物源、无饲养层的人多能干细胞培养系统 | |
| CN105039251A (zh) | 一种pH值稳定的淋巴细胞无血清培养基及其制备方法和应用 | |
| AU2001253343B2 (en) | Human ovarian mesothelial cells and methods of isolation and uses thereof | |
| CN109810939B (zh) | 一种猪腹膜间皮细胞的培养方法 | |
| JP2024054301A (ja) | シート状細胞培養物の製造方法 | |
| AU2001253343A1 (en) | Human ovarian mesothelial cells and methods of isolation and uses thereof | |
| CN115644167A (zh) | 一种胎盘组织保存液及其制备方法与应用 | |
| CN104195100A (zh) | 一种乳腺上皮细胞的体外培养方法 | |
| CA3164358A1 (fr) | Procede de fabrication et de traitement de cellules renales | |
| CN111925980A (zh) | 一种鸡卵泡颗粒的体外培养方法 | |
| Mariya et al. | Mammosphere culture of mammary cells from cynomolgus macaques (Macaca fascicularis) | |
| CN111662867A (zh) | 一种人牙髓细胞分离培养方法 | |
| CN116218771B (zh) | 一种hUC-MSCs制剂及其制备方法和应用 | |
| KR102180733B1 (ko) | 탈지우유를 유효성분으로 포함하는 줄기세포 분리용 조성물 | |
| US20190169568A1 (en) | Method for Obtaining Female Germline Stem Cells from Follicular Aspirates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11814011 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 27.05.13) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11814011 Country of ref document: EP Kind code of ref document: A1 |